Nature Communications (Dec 2019)
scRNA-seq in medulloblastoma shows cellular heterogeneity and lineage expansion support resistance to SHH inhibitor therapy
- Jennifer Ocasio,
- Benjamin Babcock,
- Daniel Malawsky,
- Seth J. Weir,
- Lipin Loo,
- Jeremy M. Simon,
- Mark J. Zylka,
- Duhyeong Hwang,
- Taylor Dismuke,
- Marina Sokolsky,
- Elias P. Rosen,
- Rajeev Vibhakar,
- Jiao Zhang,
- Olivier Saulnier,
- Maria Vladoiu,
- Ibrahim El-Hamamy,
- Lincoln D. Stein,
- Michael D. Taylor,
- Kyle S. Smith,
- Paul A. Northcott,
- Alejandro Colaneri,
- Kirk Wilhelmsen,
- Timothy R. Gershon
Affiliations
- Jennifer Ocasio
- Department of Neurology, University of North Carolina School of Medicine
- Benjamin Babcock
- Department of Neurology, University of North Carolina School of Medicine
- Daniel Malawsky
- Department of Neurology, University of North Carolina School of Medicine
- Seth J. Weir
- Department of Neurology, University of North Carolina School of Medicine
- Lipin Loo
- UNC Neuroscience Center, University of North Carolina School of Medicine
- Jeremy M. Simon
- UNC Neuroscience Center, University of North Carolina School of Medicine
- Mark J. Zylka
- UNC Neuroscience Center, University of North Carolina School of Medicine
- Duhyeong Hwang
- UNC Eshelman School of Pharmacy, University of North Carolina School of Medicine
- Taylor Dismuke
- Department of Neurology, University of North Carolina School of Medicine
- Marina Sokolsky
- UNC Eshelman School of Pharmacy, University of North Carolina School of Medicine
- Elias P. Rosen
- UNC Eshelman School of Pharmacy, University of North Carolina School of Medicine
- Rajeev Vibhakar
- Department of Pediatrics, University of Colorado Anschutz Medical Campus
- Jiao Zhang
- Developmental & Stem Cell Biology Program, The Hospital for Sick Children
- Olivier Saulnier
- Developmental & Stem Cell Biology Program, The Hospital for Sick Children
- Maria Vladoiu
- Developmental & Stem Cell Biology Program, The Hospital for Sick Children
- Ibrahim El-Hamamy
- Department of Molecular Genetics, University of Toronto
- Lincoln D. Stein
- Department of Molecular Genetics, University of Toronto
- Michael D. Taylor
- Developmental & Stem Cell Biology Program, The Hospital for Sick Children
- Kyle S. Smith
- Department of Developmental Neurobiology, St. Jude Children’s Research Hospital
- Paul A. Northcott
- Department of Developmental Neurobiology, St. Jude Children’s Research Hospital
- Alejandro Colaneri
- Department of Neurology, University of North Carolina School of Medicine
- Kirk Wilhelmsen
- Department of Neurology, University of North Carolina School of Medicine
- Timothy R. Gershon
- Department of Neurology, University of North Carolina School of Medicine
- DOI
- https://doi.org/10.1038/s41467-019-13657-6
- Journal volume & issue
-
Vol. 10,
no. 1
pp. 1 – 17
Abstract
Although the hedgehog (HH) pathway is known to be deregulated in medulloblastoma, inhibitors of the pathway have shown disappointing clinical benefit. Using single-cell sequencing in a mouse model of the disease, the authors show that the response to the HH pathway inhibitor vismodegib is cell-type specific.
